Prescient Therapeutics Limited

ASX:PTX Stock Report

Market Cap: AU$33.0m

Prescient Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

ASX:PTX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
30 Sep 24BuyAU$9,435Gavin ShepherdIndividual235,908AU$0.04

Insider Trading Volume

Insider Buying: PTX insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of PTX?
Owner TypeNumber of SharesOwnership Percentage
Institutions4,229,5600.525%
Private Companies27,142,2123.37%
Individual Insiders114,656,80314.2%
General Public659,291,21881.9%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 18.11% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
3.06%
David Kenley
24,625,332AU$1.0m-2.49%no data
2.03%
Gavin Shepherd
16,385,908AU$671.8k0%no data
1.39%
Steven Yatomi-Clarke
11,195,017AU$459.0k0%no data
1.18%
Jekl Holdings Pty Ltd
9,500,000AU$389.5k0%no data
1.15%
Andrew Stewart
9,233,176AU$378.6k0%no data
0.76%
Clinton Hopper
6,093,595AU$249.8k31.5%no data
0.72%
Boyce Pty Limited
5,809,400AU$238.2k0%no data
0.69%
Madoc Tiong
5,550,000AU$227.6k0%no data
0.62%
Catherine Shepherd
5,000,000AU$205.0k25%no data
0.58%
Dossman Pty Ltd
4,682,077AU$192.0k0%no data
0.56%
Michele Kittel
4,510,714AU$184.9k0%no data
0.56%
Anthony Kittel
4,510,714AU$184.9k0%no data
0.53%
Jakov Kulis
4,250,000AU$174.2k0%no data
0.53%
Netwealth Investments Ltd.
4,229,560AU$173.4k0%no data
0.47%
Golden Eggplant Pty Ltd
3,816,807AU$156.5k0%no data
0.43%
Sarah Daly
3,500,000AU$143.5k42.9%no data
0.43%
Richard Daly
3,500,000AU$143.5k42.9%no data
0.41%
Sb Investments Pty Ltd
3,333,928AU$136.7k0%no data
0.37%
Simone Halls
2,950,000AU$120.9k0%no data
0.37%
Anthony Halls
2,950,000AU$120.9k0%no data
0.35%
Rosamund Banyard
2,852,763AU$117.0k27.5%no data
0.35%
Phillip Holten
2,852,762AU$117.0k27.5%no data
0.25%
Vincent Fitzgerald
2,040,259AU$83.7k0%no data
0.25%
Penelope Fitzgerald
2,040,259AU$83.7k0%no data
0.049%
James Campbell
396,365AU$16.3k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:27
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Prescient Therapeutics Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paul HickmanEdison Investment Research
Joseph PantginisH.C. Wainwright & Co.